Once-daily treatment of ADHD with guanfacine: patient implications
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Once-daily treatment of ADHD with guanfacine: patient implications Brandon C StrangeDepartment of Psychiatry at The Ohio State University, Columbus, OH, USAAbstract: The standard of care for treating ADHD is to use a psychostimulant as the first line agent. Recent medical literature reports that approximately 70%–90% of patients with ADHD received some benefit from a stimulant medication. Even though psychostimulants have a high rate of efficacy, an estimated 30%–50% of children and adults may discontinue psychostimulants secondary to adverse effects or inadequate response. Guanfacine has been used for a number of years as an off label alternative to psychostimulants. This article reviews the current literature on the effectiveness of guanfacine in treating ADHD. It also introduces the preliminary data for guanfacine extended release and its effectiveness in decreasing the symptoms of ADHD.Keywords: guanfacine, alpha adrenergic agonist, attention deficit/hyperactivity disorder, impulsivity, attention
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“Clonidine is 10 times more potent than guanfacine at these presynaptic actions (Engberg and Eriksson 1991), while guanfacine appears to be more potent at postsynaptic receptors (Arnsten et al 1988).”
BackgroundU’PRICHARD, D. C., BECHTEL, W. D., ROUOT, B. M., & SNYDER, S. H. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11406-5 · Cited by 384
CHAPPELL, P. B., RIDDLE, M. A., SCAHILL, L., LYNCH, K. A., SCHULTZ, R., ARNSTEN, A., LECKMAN, J. F., & COHEN, D. J. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199509000-00010 · Cited by 250 · cited 3×
“Even though psychostimulants are still the fi rst line treatment for ADHD and atomoxetine is the only non-stimulant approved for ADHD, guanfacine may be a good alternative for children with comorbid ADHD and tic (Chappell et al 1995; Scahill et al 2001).”
BackgroundMethodTaylor, F. B., & Russo, J. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00015 · Cited by 189 · cited 2×
“Even though both guanfacine and DAMP showed improvement from placebo attention and impulsivity, all subjects stated that DAMP was the only medication that improved motivation (Taylor and Russo 2001).”
BackgroundWeiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147 · cited 1×
“Decreased appetite and gastrointestinal events are a common side effect for atomoxetine (Weiss et al 2005).”
BackgroundAoki, C. (1998) · Cerebral Cortex · doi:10.1093/cercor/8.3.269 · Cited by 138 · cited 1×
“The α 2A subtype can be found both presynaptically on NE neurons, and postsynaptically on nonNE neurons (Aoki et al 1998; Wang et al 2007).”
BackgroundPosey, D. J., Puntney, J. I., Sasher, T. M., Kem, D. L., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649084 · Cited by 127
Ramos, B. P., Stark, D., Verduzco, L., van Dyck, C. H., & Arnsten, A. F. T. (2006) · Learning & Memory · doi:10.1101/lm.298006 · Cited by 124 · cited 1×
“In animal studies, infusion of guanfacine directly into the PFC improves performance of PFC tasks (Mao et al 1999; Ramos et al 2006).”
BackgroundSorkin, E. M., & Heel, R. C. (1986) · Drugs · doi:10.2165/00003495-198631040-00003 · Cited by 106
Bellgrove, M. A., Hawi, Z., Gill, M., & Robertson, I. H. (2006) · Cortex · doi:10.1016/s0010-9452(08)70426-x · Cited by 97
Locomotor hyperactivity induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys
Ma, C.-L., Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.004 · Cited by 96 · cited 1×
“Infusions of yohimbine into the monkey PFC weaken working memory and impulse control, and induce locomotor hyperactivity, similar to the symptoms of ADHD (Ma et al 2003, 2005).”
MethodEngberg, G., & Eriksson, E. (1991) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169548 · Cited by 68
Newcorn, J. H., Schulz, K., Harrison, M., DeBellis, M. D., Udarbe, J. K., & Halperin, J. M. (1998) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70064-x · Cited by 68
Kieling, C., Genro, J. P., Hutz, M. H., & Rohde, L. A. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30636 · Cited by 65
Cited by
Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.11.005 · Cited by 142
Developments and challenges in the diagnosis and treatment of ADHD
Dias, T. G. C., Kieling, C., Graeff-Martins, A. S., Moriyama, T. S., Rohde, L. A., & Polanczyk, G. V. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-s103 · Cited by 62
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD
Duong, S., Chung, K., & Wigal, S. B. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.671295 · Cited by 42
Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers
Haney, M., Cooper, Z. D., Bedi, G., Herrmann, E., Comer, S. D., Reed, S. C., Foltin, R. W., & Levin, F. R. (2019) · Addiction Biology · doi:10.1111/adb.12621 · Cited by 31
“Guanfacine hydrochloride (Tenex®), FDA approved for the treatment of hypertension, peaks in the serum in 1–4 hours (Strange 2008), and is given multiple times per day for this indication.”
BackgroundSrour, H., Pandya, K., Flannery, A., & Hatton, K. (2018) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253218768537 · Cited by 21
Metadata
- Authors
- Strange, B.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2008-06
- Volume
- 4
- Issue
- 3
- Pages
- 499
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2018085194
- Cited by
- 45
- References
- 21
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.